Lifeboat Foundation

A team of researchers affiliated with several institutions in China has developed a hydrogel that can stop bleeding from a punctured artery. In their paper published in the journal Nature Communications, the group describes how the hydrogel was made and how well it worked on test animals.

Uncontrolled bleeding is a very serious situation, both during surgical procedures and as a result of trauma. In most cases, it is the result of damage to a major artery or an organ like the liver. In all cases, immediate action must be taken or the victim will die. Currently, treatment for such wounds involves clamping the artery and then using sutures to close the wound. In the past, researchers have attempted to create a type of glue to stem such wounds, but thus far, none of them has worked as hoped—they were either made of toxic materials or were not strong enough to stand up to the high liquid pressure in the bloodstream. In this new effort, the researchers have developed a new type of hydrogel that solves both problems.

Continue reading “A hydrogel that can stop bleeding from an artery” »

American researchers have recently published a study in the scientific journal Nature, showing promising results using steroid eye drops for shrinking down and dissolving cataracts.

At the moment cataracts is the leading cause of blindness, and can only be removed through surgery. The surgical procedure, while simple and safe, is unpleasant for the patient and often prohibitively expensive.

A ccording to the Fred Hollows Foundation, approximately 32.4 million people around the world are blind, with more than half of the cases being caused by cataracts. In the United States alone, nearly 22 million Americans who are over age 40 have cataracts, according to the American Academy of Ophthalmology.

Continue reading “Goodbye Surgery – Scientists Made Eye Drops That Dissolve Cataracts” »

Substantially earlier than indicated by most DNA-based estimates, according to new research by a UCL academic.

The research, published in Science Advances, analysed dental evolutionary rates across different hominin species, focusing on early Neanderthals. It shows that the teeth of hominins from Sima de los Huesos, Spain—ancestors of the Neanderthals—diverged from the modern human lineage earlier than previously assumed.

Sima de los Huesos is a cave site in Atapuerca Mountains, Spain, where archaeologists have recovered fossils of almost 30 people. Previous studies date the site to around 430,000 years ago (Middle Pleistocene), making it one of the oldest and largest collections of human remains discovered to date.

Continue reading “Neanderthals and modern humans diverged at least 800,000 years ago” »

The world recently acknowledged the power of alternative cancer treatments by awarding the 2018 Nobel Prize in Medicine to Dr. James P. Allison and Dr. Tasuku Honjo for their work in immunotherapy. More specifically on checkpoint inhibitor therapies.

Until recently many in the scientific community had dismissed immunotherapy as a viable cancer treatment. Nevertheless, Allison and Honjo persevered and their breakthrough has allowed for the classification of new drugs and treatments that may help patients have run out of options.

Ironically, while many in the mainstream are barely learning of immunotherapy, a hospital in Mexico, CHIPSA Hospital, has been working with these treatments for over 38 year and often under fire from public ridicule that their treatments are strange and ineffective.

Continue reading “Alternative Cancer Treatments Brought to Legitimacy at Scientific Forum in San Diego” »

Researchers create altered synthetic genome, in move with potential medical benefits.

Nicola Bagalà and Michael Nuschke take a look at the future of pensions and how the possible defeat of age-related diseases will affect them.

If you work in social security, it’s possible that your nightmares are full of undying elderly people who keep knocking on your door for pensions that you have no way of paying out. Tossing and turning in your bed, you beg for mercy, explaining that there’s just too many old people who need pensions and not enough young people who could cover for it with their contributions; the money’s just not there to sustain a social security system that, when it was conceived in the mid-1930s, didn’t expect that many people would ever make it into their 80s and 90s. Your oneiric persecutors won’t listen: they gave the country the best years of their lives, and now it’s time for the country to pay them their due.

When you wake up, you’re relieved to realize that there can’t be any such thing as people who have ever-worsening degenerative diseases yet never die from them, but that doesn’t make your problem all that better; you still have quite a few old people, living longer than the pension system had anticipated, to pay pensions to, and the bad news is that in as little as about 30 years, the number of 65+ people worldwide will skyrocket to around 2.1 billion, growing faster than all younger groups put together [1]. Where in the world is your institution going to find the budget?

Continue reading “The Future of Pensions” »

But they don’t. Instead, they are less likely to develop or die of this enigmatic disease. The same is true of elephants and dinosaurs’ living relatives, birds. Marc Tollis, an assistant professor in the School of Informatics, Computing, and Cyber Systems at Northern Arizona University, wants to know why.

Tollis led a team of scientists from Arizona State University, the University of Groningen in the Netherlands, the Center for Coastal Studies in Massachusetts and nine other institutions worldwide to study potential cancer suppression mechanisms in cetaceans, the mammalian group that includes whales, dolphins and porpoises. Their findings, which picked apart the genome of the humpback whale, as well as the genomes of nine other cetaceans, in order to determine how their cancer defenses are so effective, were published today in Molecular Biology and Evolution.

The study is the first major contribution from the newly formed Arizona Cancer and Evolution Center or ACE, directed by Carlo Maley under an $8.5 million award from the National Cancer Institute. Maley, an evolutionary biologist, is a researcher at ASU’s Biodesign Virginia G. Piper Center for Personalized Diagnostics and professor in the School of Life Sciences. He is a senior co-author of the new study.

Continue reading “How whales defy the cancer odds: Good genes” »

In a medical first, the children were treated with genetically engineered T-cells from another person.